Share on Facebook Share on Twitter

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Comparison of Vaccines
Personally, I felt the claims of "get whatever vaccine you are offered" was "paternalistic" (as the opinion piece put it) and obviously not in the best interest of each individual, when the J&J vaccine received EUA. J&J's one-dose efficacy against infection was no better than the efficacy of one-dose of the mRNA vaccines. Its full-course efficacy against infection was considerably less. The argument was that its efficacy against major illness was sufficiently high that it could be offered.

I felt that the CDC or FDA could have pointed out that a single dose of either mRNA was at least as good and that people could choose to stop after a single dose, or to delay the 2nd dose.

The single-dose feature for J&J didn't need to be. J&J could have (maybe they did?) conducted a study of a two-dose regime. Likewise, the mRNA vaccines had most of the data for a single-dose recommendation. They could have gone for that.

I suspect marketing played into the companies' positions. The mRNA companies made more profit (and those getting the vaccines got better outcomes) with a two-dose regimen. Why offer a single-dose regimen? J&J was late to the game. They probably wouldn't get much of the market share with yet another two-dose regimen. So, they chose to try to get the population that wanted a single-dose regimen. I believe the CDC/FDA was complicit by the way they didn't say that the single-dose regimen was inferior to the two-dose vaccines. If their feeling was that a single-dose regimen would get more people vaccinated, with an overall reduction in illness & death, that's a good thing.

Notice that we're not seeing a 4th vaccine in the approval process. Who would their customers be?

While the article has "Data from Washington, DC, in May 2021 found that 80% of new COVID-19 cases were in Black individuals, although they make up only about 45% of the population", I will note that in Santa Clara County, when you look at the races, the African-American population has slight fewer cases than one would expect based on their percent of the population. Indeed, that is true for California as well (5% of cases; 6% of population). To characterize the imbalance among population, I'd expect that economic situation has a higher correlation than race. (Things like education, industry, religion, political preference, geographic location may also correlate with inequity of case rates.)

This opinion piece didn't try to investigate or quantitize the reasons for inequities in cases or vaccination rates; it just offered possibilities without prioritization of which are most widespread and which are more easily overcome.

Messages In This Thread
Comparison of Vaccines - by M_T - 05-19-2021, 04:14 AM
RE: Comparison of Vaccines - by Hurlburt88 - 10-27-2021, 11:08 AM
RE: Comparison of Vaccines - by M_T - 10-27-2021, 05:44 PM
RE: Comparison of Vaccines - by Hurlburt88 - 10-28-2021, 11:24 AM
RE: Comparison of Vaccines - by Hurlburt88 - 11-29-2021, 12:15 PM
RE: Comparison of Vaccines - by M_T - 11-30-2021, 02:48 AM
RE: Comparison of Vaccines - by Hurlburt88 - 12-25-2021, 08:29 AM
RE: Comparison of Vaccines - by M_T - 12-28-2021, 01:15 AM

Forum Jump:

Users browsing this thread: